DCGI approves India Biotech nozzle vaccine for third phase trial

- Nozzle vaccine can be taken six months after the second dose of Corona

- Nozzle vaccine will be tested on five thousand: 50% will be covshield recipients and half will be covacin recipients

New Delhi: DCGI's expert committee (SEC) has approved the third phase trial of India Biotech's intranasal vaccine and the third phase study of booster doses. The "nozzle vaccine" is recognized as a booster dose. An important meeting of the expert committee was held on Tuesday in this regard. It has approved this nozzle vaccine for the third phase of booster dose study, but also for its emergency use.

In a landmark decision taken today (Wednesday), the Drug Controller General of India has approved the trial of this nozzle vaccine. In fact, Bharat Biotech, while seeking approval for its new vaccine, said that for those who have taken two doses of corona-vaccine as per the rules, this "nozzle vaccine" may be the most successful. Yes, and its use as a best option is likely to work. The vaccine is to be tested on 5,000 people. Out of 5,000, 60 per cent will be covshield recipients and 20 per cent will be covacin vaccine. Booster doses will be used on people who have taken both doses.